The drugmaker is scaling back at sites in Indianapolis that make active pharmaceutical ingredients for the Humalog and Humulin insulin meds, as well as for the Forteo osteoporosis treatment. UPDATE: A Lilly spokesman tells us that 430 of the jobs will come from manufacturing, no sites are being closed and API production isn’t being shifted elsewhere. The drugmaker employs about 12,000 people in Indianapolis.

“We are constantly assessing our manufacturing capacity and taking the necessary steps to align it with the demands of the business. In particular, we must align our production capacity with anticipated customer demands over a time period in which some products will lose patent protection while other new products are launched,” says Lilly’s newly promoted ceo John Lechleiter, in a statement. This is his first big announcement, by the way, since succeeding Sid Taurel.